MA38307B1 - 4-hydroxy-2-méthyl-5-(propan-2-ylidène)cyclohex-3-ènecarbaldéhyde pour la prévention et le traitement d'une maladie cognitive, neurodégénérative ou neuronale - Google Patents
4-hydroxy-2-méthyl-5-(propan-2-ylidène)cyclohex-3-ènecarbaldéhyde pour la prévention et le traitement d'une maladie cognitive, neurodégénérative ou neuronaleInfo
- Publication number
- MA38307B1 MA38307B1 MA38307A MA38307A MA38307B1 MA 38307 B1 MA38307 B1 MA 38307B1 MA 38307 A MA38307 A MA 38307A MA 38307 A MA38307 A MA 38307A MA 38307 B1 MA38307 B1 MA 38307B1
- Authority
- MA
- Morocco
- Prior art keywords
- neurodegenerative
- cognitive
- prevention
- treatment
- enecarbaldehyde
- Prior art date
Links
- 230000001149 cognitive effect Effects 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 230000001537 neural effect Effects 0.000 title abstract 2
- 230000000626 neurodegenerative effect Effects 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- NESSRRDBNBBGEK-UHFFFAOYSA-N 4-hydroxy-2-methyl-5-propan-2-ylidenecyclohex-3-ene-1-carbaldehyde Chemical compound CC1C=C(O)C(=C(C)C)CC1C=O NESSRRDBNBBGEK-UHFFFAOYSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C47/00—Compounds having —CHO groups
- C07C47/38—Unsaturated compounds having —CHO groups bound to carbon atoms of rings other than six—membered aromatic rings
- C07C47/46—Unsaturated compounds having —CHO groups bound to carbon atoms of rings other than six—membered aromatic rings containing hydroxy groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/11—Aldehydes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Psychology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La présente invention concerne un composé pharmaceutique ayant la formule (1), ou un sel pharmaceutiquement acceptable de celui-ci, pour utilisation dans la prévention ou le traitement d'une maladie cognitive, neurodégénérative ou neuronale telle que la maladie d'alzheimer, une composition pharmaceutique et un procédé de préparation d'une composition pharmaceutique.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| LU92126A LU92126B1 (fr) | 2012-12-31 | 2012-12-31 | Composé pharmaceutique pour la prévention et le traitement d'un trouble ou d'une maladie de la mémoire, neurodégénérative ou neuronale |
| PCT/EP2013/076936 WO2014102090A1 (fr) | 2012-12-31 | 2013-12-17 | 4-hydroxy-2-méthyl-5-(propan-2-ylidène)cyclohex-3-ènecarbaldéhyde pour la prévention et le traitement d'une maladie cognitive, neurodégénérative ou neuronale |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA38307A1 MA38307A1 (fr) | 2016-12-30 |
| MA38307B1 true MA38307B1 (fr) | 2017-11-30 |
Family
ID=47470067
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA38307A MA38307B1 (fr) | 2012-12-31 | 2013-12-17 | 4-hydroxy-2-méthyl-5-(propan-2-ylidène)cyclohex-3-ènecarbaldéhyde pour la prévention et le traitement d'une maladie cognitive, neurodégénérative ou neuronale |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US9284250B2 (fr) |
| EP (1) | EP2938337A1 (fr) |
| JP (1) | JP6699961B2 (fr) |
| KR (1) | KR102104155B1 (fr) |
| CN (1) | CN104884052B (fr) |
| AR (1) | AR094318A1 (fr) |
| AU (1) | AU2013369491B2 (fr) |
| BR (1) | BR112015015509B1 (fr) |
| CA (1) | CA2895429C (fr) |
| CL (1) | CL2015001881A1 (fr) |
| EA (1) | EA029650B1 (fr) |
| HK (1) | HK1214517A1 (fr) |
| IL (1) | IL239622B (fr) |
| JO (1) | JO3483B1 (fr) |
| LU (1) | LU92126B1 (fr) |
| MA (1) | MA38307B1 (fr) |
| MX (1) | MX369590B (fr) |
| MY (1) | MY171832A (fr) |
| NZ (1) | NZ710131A (fr) |
| PE (1) | PE20151424A1 (fr) |
| PH (1) | PH12015501402B1 (fr) |
| SG (1) | SG11201504744WA (fr) |
| TN (1) | TN2015000275A1 (fr) |
| TW (1) | TWI590819B (fr) |
| UA (1) | UA117822C2 (fr) |
| UY (1) | UY35253A (fr) |
| WO (1) | WO2014102090A1 (fr) |
| ZA (1) | ZA201505057B (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3421482A1 (fr) | 2012-12-21 | 2019-01-02 | Alios Biopharma, Inc. | Nucléosides substitués, nucléotides et analogues de ceux-ci |
| EP3568460A4 (fr) * | 2017-01-13 | 2020-09-23 | Bened Biomedical Co., Ltd. | Nouvelle bactérie lactique et ses applications |
| KR102017415B1 (ko) * | 2018-02-13 | 2019-09-02 | 연세대학교 산학협력단 | 뇌 신경 손상 완화용 조성물 |
| CN108813453A (zh) * | 2018-05-23 | 2018-11-16 | 青岛大学 | 一种防治帕金森病的食用组合物 |
| EP4069007B1 (fr) | 2019-12-02 | 2024-02-07 | Philip Morris Products S.A. | Dispositif de chicha doté d'un bac |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001068576A1 (fr) * | 2000-03-10 | 2001-09-20 | Applied Genetics Incorporated Dermatics | Composes dermatologiques |
| CN1511520A (zh) * | 2002-12-31 | 2004-07-14 | �й�ҽѧ��ѧԺҩ���о��� | 丁二酸酯衍生物治疗痴呆症的用途 |
| US20060241133A1 (en) * | 2003-03-14 | 2006-10-26 | Shearman Mark S | Electrically variable pneumatic structural element |
-
2012
- 2012-12-31 LU LU92126A patent/LU92126B1/fr active
-
2013
- 2013-12-17 SG SG11201504744WA patent/SG11201504744WA/en unknown
- 2013-12-17 AU AU2013369491A patent/AU2013369491B2/en active Active
- 2013-12-17 UA UAA201507037A patent/UA117822C2/uk unknown
- 2013-12-17 KR KR1020157020805A patent/KR102104155B1/ko active Active
- 2013-12-17 CA CA2895429A patent/CA2895429C/fr active Active
- 2013-12-17 WO PCT/EP2013/076936 patent/WO2014102090A1/fr not_active Ceased
- 2013-12-17 EP EP13808014.8A patent/EP2938337A1/fr not_active Ceased
- 2013-12-17 CN CN201380069044.3A patent/CN104884052B/zh active Active
- 2013-12-17 EA EA201591021A patent/EA029650B1/ru unknown
- 2013-12-17 NZ NZ710131A patent/NZ710131A/en unknown
- 2013-12-17 JP JP2015550024A patent/JP6699961B2/ja active Active
- 2013-12-17 HK HK16102495.8A patent/HK1214517A1/zh unknown
- 2013-12-17 PE PE2015001180A patent/PE20151424A1/es unknown
- 2013-12-17 MX MX2015008520A patent/MX369590B/es active IP Right Grant
- 2013-12-17 MY MYPI2015702083A patent/MY171832A/en unknown
- 2013-12-17 US US14/758,343 patent/US9284250B2/en active Active
- 2013-12-17 BR BR112015015509-0A patent/BR112015015509B1/pt active IP Right Grant
- 2013-12-17 MA MA38307A patent/MA38307B1/fr unknown
- 2013-12-27 AR ARP130105072A patent/AR094318A1/es not_active Application Discontinuation
- 2013-12-30 UY UY0001035253A patent/UY35253A/es not_active Application Discontinuation
- 2013-12-30 TW TW102148993A patent/TWI590819B/zh active
- 2013-12-30 JO JOP/2013/0390A patent/JO3483B1/ar active
-
2015
- 2015-06-16 TN TNP2015000275A patent/TN2015000275A1/fr unknown
- 2015-06-18 PH PH12015501402A patent/PH12015501402B1/en unknown
- 2015-06-24 IL IL239622A patent/IL239622B/en active IP Right Grant
- 2015-06-30 CL CL2015001881A patent/CL2015001881A1/es unknown
- 2015-07-14 ZA ZA2015/05057A patent/ZA201505057B/en unknown
-
2016
- 2016-03-14 US US15/069,118 patent/US9611205B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA47368B1 (fr) | N-[4-fluoro-5-[[(2s,4s)-2-méthyl-4-[(5-méthyl-1,2,4-oxadiazol-3-yl)méthoxy]-1-pipéridyl]méthyl]thiazol-2-yl]acétamide utilisés en tant qu'inhibiteur d'oga | |
| MA38227A1 (fr) | Nouveaux composés bicycliques et leur utilisation en tant qu'agents antibactériens et inhibiteurs de ?-lactamase | |
| MA37866B1 (fr) | Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur | |
| MA38661A1 (fr) | Composés hétéro-aromatiques et leur utilisation en tant que ligands d1 de la dopamine | |
| MA35128B1 (fr) | Nouveaux dérivés d'imidazole utiles pour le traitement de l'arthrite | |
| MA43169B1 (fr) | Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma | |
| MA39219B1 (fr) | Nouveaux composés inhibiteurs de la kinase lrrk2 utilisés pour le traitement du parkinson, de l’alzheimer et de la sclérose latérale amyotrophique | |
| MA37888A1 (fr) | Composition pharmaceutique enrobée contenant du régorafenib | |
| MA35351B1 (fr) | Nouveau dérivé 1,2,3,4- tétrahydroquinoléine utile pour le traitement du diabète. | |
| MA35826B1 (fr) | Triazolopyridines substituées et leur utilisation à titre d'inhibiteurs de ttk | |
| MA38307A1 (fr) | 4-hydroxy-2-méthyl-5-(propan-2-ylidène)cyclohex-3-ènecarbaldéhyde pour la prévention et le traitement d'une maladie cognitive, neurodégénérative ou neuronale | |
| MA35246B1 (fr) | 1,3-oxazines en tant qu'inhibiteurs de bace1 et/ou de bace2 | |
| MA44948A1 (fr) | Inhibiteurs de bace 1 | |
| MA37886A1 (fr) | Nouvelles pyridinones bicycliques | |
| TN2016000188A1 (fr) | Derives de purines 2,6-substitues et leur utilisation dans le traitement de troubles proliferatifs. | |
| MA38260A1 (fr) | Nouveaux dérivés de cyclohexyl et quinuclidinyl carbamate ayant une activité d'agoniste adrénergique beta2 et une activité d'antagoniste muscarinique m3 | |
| MA40955A (fr) | 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 | |
| MA39165A1 (fr) | Dérivés de benzimidazole-proline pour leurs utilisations dans le traitement du syndrome des etats crepusculaires | |
| MA37763B1 (fr) | Difluoro-hexahydro-cyclopentaoxazinyles et difluoro-hexahydro-benzooxazinyles en tant qu'inhibiteurs de bace1 | |
| MA38358A1 (fr) | Formulations de composés organiques | |
| MA43913A (fr) | Modulateurs allostériques positifs du récepteur m1 muscarinique | |
| MA38009A1 (fr) | Composes d'azaindoline substitues qui ont une activite inhibitrice de la proteine d'apoptose pour leurs utilisations dans le traitement et/ou la prophylaxie du cancer | |
| MA39447A1 (fr) | (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine | |
| MA39229A1 (fr) | Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines | |
| MA37849A1 (fr) | Dérivés de diazépinone à utiliser pour le traitement du syndrome de l'x fragile, de la maladie de parkinson ou de la maladie du reflux |